

BIM-26108	N-Ac-D-Ala-His-Trp-Ala-Val-Gly-His-LeuΨ[CH <sub>2</sub> NH]Leu-NH <sub>2</sub> GRP (19-27)	841	>1000
BIM-26113	D-Phe-Gln-Trp-Ala-Val-Gly-His-LeuΨ[CH <sub>2</sub> NH]Leu-NH <sub>2</sub> Litorin	5.8	9
BIM-26114	D-Nal-Gln-Trp-Ala-Val-Gly-His-LeuΨ[CH <sub>2</sub> NH]Leu-NH <sub>2</sub> Litorin	23.5	28
BIM-26120	pGlu-Gln-Trp-Ala-Val-Gly-His-Sta-NH <sub>2</sub> (SEQ ID NO:4) Litorin	150	165
BIM-26122	D-Phe-Gln-Trp-Ala-Val-Gly-His-Leu-NH <sub>2</sub> Litorin	5.9	28.6
BIM-26136	D-Nal-Gln-Trp-Ala-Val-Gly-His-LeuΨ[CH <sub>2</sub> NH]Phe-NH <sub>2</sub> Litorin	1.4	3.3
BIM-26182	D-Cpa-Gln-Trp-Ala-Val-Gly-His-β-Leu-NH <sub>2</sub> Litorin	0.88	4.77--

In the claims:

Amend claim 4 as follows:

--4. (Amended) The therapeutic peptide of claim 2 of the formula:

p-Glu-Gln-Trp-Ala-Val-Gly-His-statine-amide (SEQ ID NO:4).--